References:
[1] Henter JI, Horne A, Aricó M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer . 2007;48(2):124-131. doi:10.1002/pbc.21039
[2] Lehmberg K, Nichols KE, Henter JI, et al. Consensus recommendations for the diagnosis and management of hemophagocytic lymphohistiocytosis associated with malignancies. Haematologica . 2015;100(8):997-1004. doi:10.3324/haematol.2015.123562
[3] AALL1732: A Phase 3 Randomized Trial of Inotuzumab Ozogamicin for Newly Diagnosed High-Risk B-ALL; Risk Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
[4] Bracaglia C, Marafon DP, Caiello I, et al. High levels of interferon-gamma (IFNγ) in macrophage activation syndrome (MAS) and CXCL9 levels as a biomarker for IFNγ production in MAS. Pediatr Rheumatol Online J . 2015;13(Suppl 1):O84. Published 2015 Sep 28. doi:10.1186/1546-0096-13-S1-O84
[5] Locatelli F, Jordan MB, Allen C, et al. Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis. N Engl J Med . 2020;382(19):1811-1822. doi:10.1056/NEJMoa1911326
[6] AALL1231: A Phase III Randomized Trial Investigating Bortezomib on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy)
[7] Wang J, Wang Y, Wu L, et al. Ruxolitinib for refractory/relapsed hemophagocytic lymphohistiocytosis. Haematologica . 2020;105(5):e210-e212. doi:10.3324/haematol.2019.222471
[8] van Enckevort FH, Netea MG, Hermus AR, et al. Increased susceptibility to systemic candidiasis in interleukin-6 deficient mice. Med Mycol . 1999;37(6):419-426. doi:10.1046/j.1365-280x.1999.00247.x
[9] Tabata C, Tabata R. Possible prediction of underlying lymphoma by high sIL-2R/ferritin ratio in hemophagocytic syndrome. Ann Hematol . 2012;91(1):63-71. doi:10.1007/s00277-011-1239-7